Atezolizumab/ipilimumab/nivolumabLymphocytic colitis : 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1700卷 / 1期

关键词：

D O I：

10.1007/s40278-018-45619-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：47 / 47

相关论文

共 50 条

[31] Ipilimumab/nivolumabHypophysitis: 3 case reports
Reactions Weekly, 2020, 1833 (1) : 216 - 216
[32] Ipilimumab/nivolumabColitis: 3 case reports
Reactions Weekly, 2022, 1928 (1) : 213 - 213
[33] Ipilimumab/nivolumabPneumonitis: 3 case reports
Reactions Weekly, 2015, 1563 (1) : 127 - 127
[34] Atezolizumab/bevacizumabImmune-mediated colitis and proteinuria: 2 case reports
Reactions Weekly, 2024, 2021 (1) : 89 - 89
[35] Atezolizumab/durvalumab/ipilimumabPneumonitis: 3 case reports
Reactions Weekly, 2022, 1912 (1) : 101 - 101
[36] Atezolizumab/PembrolizumabVarious toxicity: 3 case reports
Reactions Weekly, 2025, 2050 (1) : 88 - 88
[37] Ipilimumab/nivolumabGrade 3 colitis: case report
Reactions Weekly, 2023, 1986 (1) : 222 - 222
[38] Atezolizumab/bevacizumabVarious toxicities: 3 case reports
Reactions Weekly, 2023, 1944 (1) : 125 - 125
[39] Ipilimumab/nivolumab/pembrolizumabAcute hepatitis, colitis and diverticulitis: 4 case reports
Reactions Weekly, 2018, 1725 (1) : 185 - 185
[40] Ipilimumab/nivolumab/pembrolizumabPsoriasis flares, colitis and rash: 15 case reports
Reactions Weekly, 2022, 1888 (1) : 209 - 209

← 1 2 3 4 5 →